Καρδιολογική Γνώμη - Εθνικό και Καποδιστριακό Πανεπιστήμιο ...

Βιοχημικοί και διατροφικοί παράγοντες που επηρεάζουν τα επίπεδα PAF και τα ένζυμα μεταβολισμού του στον άνθρωπο109healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol2008; 51:913-9.39. Sabatine MS, Morrow DA, O’Donoghue M, et al. Prognostic utility oflipoprotein-associated phospholipase A2 for cardiovascular outcomesin patients with stable coronary artery disease. Arterioscler ThrombVasc Biol 2007; 27:2463-9.40. Mockel M, Muller R, Vollert JO, et al. Lipoprotein-associated phospholipaseA2 for early risk stratification in patients with suspectedacute coronary syndrome: a multi-marker approach: the North Wuerttembergand Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol2007; 96:604-12.41. Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex onlipoprotein-associated phospholipase A2 levels: Observations fromthe Dallas Heart Study. Atherosclerosis 2007; 199:110-115.42. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associatedphospholipase A2 does not predict mortality or new ischaemic eventsin acute coronary syndrome patients. Eur Heart J 2007; 28:699-704.43. Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP.Lipoprotein-associated phospholipase A2 predicts progression of cardiacallograft vasculopathy and increased risk of cardiovascular eventsin heart transplant patients. Transplantation 2008; 85:963-8.44. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associatedphospholipase A2, high-sensitivity C-reactive protein, and risk for incidentcoronary heart disease in middle-aged men and women in theAtherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42.45. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM.Distribution and correlates of lipoprotein-associated phospholipaseA2 in an elderly cohort: the Cardiovascular Health Study. J Am GeriatrSoc 2008; 56:792-9.46. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associatedphospholipase A2 adds to risk prediction of incident coronaryevents by C-reactive protein in apparently healthy middle-agedmen from the general population: results from the 14-year follow-up ofa large cohort from southern Germany. Circulation 2004; 110:1903-8.47. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiologyof Lp-PLA(2): distribution and correlation with cardiovascularrisk factors in a population-based cohort. Atherosclerosis 2007;190:388-96.48. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH. Theassociation between lipoprotein-associated phospholipase A2 andcardiovascular disease and total mortality in vascular medicine patients.J Vasc Surg 2007; 46:500-6.49. El-Saed A, Sekikawa A, Zaky RW, et al. Association of lipoproteinassociatedphospholipase A2 with coronary calcification among Americanand Japanese men. J Epidemiol 2007; 17:179-85.50. Rana JS, Arsenault BJ, Despres JP, et al. Inflammatory biomarkers, physicalactivity, waist circumference, and risk of future coronary heartdisease in healthy men and women. Eur Heart J 2009.51. Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipaseA2 activity is associated with coronary artery disease and markers ofoxidative stress: a case-control study. Am J Clin Nutr 2008; 88:630-7.52. Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein-associated phospholipaseA2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results fromthe Bruneck study. Eur Heart J 2009; 30:107-15.53. Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, DemopoulosCA, Tselepis AD. Platelet-activating factor formation during oxidativemodification of low-density lipoprotein when PAF-acetylhydrolase hasbeen inactivated. Biochim Biophys Acta 1994; 1212:353-60.54. Detopoulou P, Nomikos T, Fragopoulou E, et al. Lipoprotein-associatedphospholipase A2 (Lp-PLA 2 ) activity, platelet-activating factoracetylhydrolase (PAF-AH) in leukocytes and body composition in healthyadults. Lipids Health Dis 2009; 8:19.55. Carallo C, Mancuso G, Mauro G, et al. Hepatic steatosis, carotid atherosclerosisand metabolic syndrome: the STEATO Study. J Gastroenterol2009; 44:1156-61.56. Grundy SM. Gamma-glutamyl transferase: another biomarker for metabolicsyndrome and cardiovascular risk. Arterioscler Thromb VascBiol 2007; 27:4-7.57. Verouti SN, Fragopoulou E, Karantonis HC, et al. PAF effects on MCP-1 and IL-6 secretion in U-937 monocytes in comparison with oxLDLand IL-1beta effects. Atherosclerosis 2011; 219:519-25.58. Zhang H, Forman HJ. Redox regulation of gamma-glutamyl transpeptidase.Am J Respir Cell Mol Biol 2009; 41:509-15.59. Karantonis HC, Antonopoulou S, Demopoulos CA. Antithrombotic lipidminor constituents from vegetable oils. Comparison between oliveoils and others. J Agric Food Chem 2002;50:1150-60.60. Fragopoulou E, Antonopoulou S, Nomikos T, Demopoulos CA. Structureelucidation of phenolic compounds from red/white wine with antiatherogenicproperties. Biochim Biophys Acta 2003; 1632:90-9.61. Panayiotou A, Samartzis D, Nomikos T, et al. Lipid fractions with aggregatoryand antiaggregatory activity toward platelets in fresh andfried cod (Gadus morhua): correlation with platelet-activating factorand atherogenesis. J Agric Food Chem 2000; 48:6372-9.62. Rementzis J, Antonopoulou S, Argyropoulos D, Demopoulos CA. Biologicallyactive lipids from S. scombrus. Adv Exp Med Biol 1996;416:65-72.63. Koussissis S, Semidalas C, Hadzistavrou EC, Kalyvas V, AntonopoulouS, Demopoulos C. PAF antagonists in foods: Isolation and identificationof PAF in honey and wax. Rev Fr Corp Gras 1994; 41:127-132.64. Antonopoulou S, Semidalas C, Koussissis S, Demopoulos C. Platelet-Activating Factor (PAF) antagonists in foods. A study of lipids, withPAF or anti-PAF like-activity, in cow’s milk and yoghurt. J Agric FoodChem 1996; 44:3047-3051.65. Lim H, Kubota K, Kobayashi A, Seki T, Ariga T. Inhibitory effect ofsulfur-containing compounds in Scorodocarpus borneensis Becc. onthe aggregation of rabbit platelets. Biosci Biotechnol Biochem 1999;63:298-301.66. Phillips C, Poyser NL. Inhibition of platelet aggregation by onion extracts.Lancet 1978; 1:1051-2.67. Karantonis HC, Fragopoulou E, Antonopoulou S, Rementzis J, PhenekosC, Demopoulos CA. Effect of fast-food Mediterranean-type dieton type 2 diabetics and healthy human subjects’ platelet aggregation.Diabetes Res Clin Pract 2006; 72:33-41.68. Pellegrini N, Serafini M, Colombi B, et al. Total antioxidant capacityof plant foods, beverages and oils consumed in Italy assessed by threedifferent in vitro assays. J Nutr 2003; 133:2812-9.69. Brighenti F, Valtuena S, Pellegrini N, et al. Total antioxidant capacityof the diet is inversely and independently related to plasma concentrationof high-sensitivity C-reactive protein in adult Italian subjects.Br J Nutr 2005; 93:619-25.70. Detopoulou P, Panagiotakos DB, Chrysohoou C, et al. Dietary antioxidantcapacity and concentration of adiponectin in apparently healthyadults: the ATTICA study. Eur J Clin Nutr 2010; 64:161-8.71. Steptoe A, Gibson EL, Vuononvirta R, et al. The effects of chronictea intake on platelet activation and inflammation: a double-blindplacebo controlled trial. Atherosclerosis 2007; 193:277-82.72. Howard KM, Abdel-Al M, Ditmyer M, Patel N. Lipopolysaccharide andplatelet-activating factor stimulate expression of platelet-activatingfactor acetylhydrolase via distinct signaling pathways. Inflamm Res2011; 60:735-44.